Synthesis, crystal structures and anti-inflammatory activity of four 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidone derivatives

Crystal structure of (E)-N′-(1-(3-chloro-4-fluorophenyl)ethylidene)-4-hydroxy – tetrahydrofuran (2/1), C17H16ClFN2O2.5

C17H16ClFN2O2.5, monoclinic, P21/n (no. 14), a = 7.4495(6) Å, b = 16.5328(13) Å, c = 12.8519(10) Å, β = 91.329(1)°, V = 1582.4(2) Å3, Z = 4, R gt (F) = 0.0508, wR ref (F 2) = 0.1461, T = 100(2) K.

Trifluoromethyl-substituted 3,5-bis(arylidene)-4-piperidones as potential anti-hepatoma and anti-inflammation agents by inhibiting NF-кB activation

Some methoxy-, hydroxyl-, pyridyl-, or fluoro-substituted 3,5-bis(arylidene)-4-piperidones (BAPs) could reduce inflammation and promote hepatoma cell apoptosis by inhibiting activation of NF-κB, especially after introduction of trifluoromethyl. Herein, a series of trifluoromethyl-substituted BAPs (4-30) were synthesised and the biological activities were evaluated. We successfully found the most potential 16, which contains three trifluoromethyl substituents and exhibits the best anti-tumour and anti-inflammatory activities. Preliminary mechanism research revealed that 16 could promote HepG2 cell apoptosis in a dose-dependent manner by down-regulating the expression of Bcl-2 and up-regulating the expression of Bax, C-caspase-3. Meanwhile, 16 inhibited activation of NF-κB by directly inhibiting the phosphorylation of p65 and IκBα induced by LPS, together with indirectly inhibiting MAPK pathway, thereby exhibiting both anti-hepatoma and anti-inflammatory activities. Molecular docking confirmed that 16 could bind to the active sites of Bcl-2, p65, and p38 reasonably. The above results suggested that 16 has enormous potential to be developed as a multifunctional agent for the clinical treatment of liver cancers and inflammatory diseases.

Crystal structure of (3E,5E)-3,5-bis-4-methoxy-3-(trifluoromethyl)benzylidene)-1-methylpiperidin-4-one, C24H21F6NO3

C24H21F6NO3, monoclinic, P21/c (no. 14), a = 16.6493(9) Å, b = 15.3005(8) Å, c = 8.8554(5) Å, β = 99.746(6)°, V = 2223.3(2) Å3, Z = 4, R gt (F) = 0.0444, wR ref (F 2) = 0.1094, T = 100 K.

Exploration of Noncovalent Interactions, Chemical Reactivity, and Nonlinear Optical Properties of Piperidone Derivatives: A Concise Theoretical Approach

The organic compounds with a π-bond system lead to electric charge delocalization which enables them to reveal fascinating nonlinear optical properties. Mono-carbonyl curcuminoids also have an appealing skeleton from the conjugation view point. Interesting chemical structures of the 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidone derivatives motivated us to perform density functional theory (DFT)-based studies. Therefore, computations using the B3LYP/6-311G(d,p) functional of DFT were executed to explore geometric parameters, highest occupied molecular orbital (HOMO)-lowest unoccupied molecular orbital (LUMO) energies, and natural bond orbital (NBO) analyses. Moreover, three different functionals such as HF, B3LYP, and M06 with the 6-311G(d,p) basis set were used to investigate the average polarizability ⟨α⟩ and first hyperpolarizability (β_tot)-based properties of all compounds. A good concurrence among calculated and experimental parameters was obtained through root mean square error calculations. The molecular stability of piperidone derivatives was examined using the Hirshfeld surface and NBO analyses. Natural population analysis was also performed to obtain insights about atomic charges. Calculated HOMO-LUMO energies showed that charge transfer interactions take place within the molecules. Moreover, global reactivity parameters including electronegativity, chemical hardness, softness, ionization potential, and electrophilicity were calculated using the HOMO and LUMO energies. The average polarizability ⟨α⟩ and first hyperpolarizability (β_tot) values of all compounds were observed to be larger in magnitude at the aforesaid functional than the standard compound.

The crystal structure of (E)-N′-(1-(3-chloro-4-fluorophenyl) ethylidene)-2-hydroxybenzohydrazide, C15H12ClFN2O2

C15H12ClFN2O2, monoclinic, P21/c (no. 14), a = 13.9210(13) Å, b = 13.2329(15) Å, c = 18.7191(19) Å, β = 126.250(2)°, V = 2780.9(5) Å3, Z = 8, R gt(F) = 0.0499, wR ref(F 2) = 0.1420, T = 293(2) K.

Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18ClF3N2O3S

C25H18ClF3N2O3S, monoclinic, P21/n (no. 14), a = 9.9087(5) Å, b = 21.7843(10) Å, c = 10.2512(6) Å, β = 94.749(5)°, V = 2205.2(2) Å3, Z = 4, R gt(F) = 0.0448, wR ref(F 2) = 0.1028, T = 100 K.

Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-bromophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18BrF3N2O3S

C25H18BrF3N2O3S, monoclinic, P21/n (no. 14), a = 9.9295(11) Å, b = 21.755(2) Å, c = 10.2358(11) Å, β = 95.022(10)°, V = 2202.6(4) Å3, Z = 4, R gt(F) = 0.0373, wR ref(F 2) = 0.0795, T = 100(1) K.

Crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-acetamidophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one-methanol-hydrate (2/1/1), C53H50F2N6O10S2

C53H50F2N6O10S2, monoclinic, P21/n (no. 14), a = 15.088(5) Å, b = 23.560(9) Å, c = 15.401(6) Å, β = 112.254(5)°, V = 5067(3) Å3, Z = 4, R gt(F) = 0.0509, wR ref(F 2) = 0.1336, T = 298(2) K.

Crystal structure of (3E,5E)-3,5-bis(3-nitrobenzylidene)-1-((4-(trifluoromethyl)phenyl)sulfonyl)piperidin-4-one — dichloromethane (2/1), C53H38Cl2F6N6O14S2

C53H38Cl2F6N6O14S2, triclinic, P1̄ (no. 2), a = 12.1975(6) Å, b = 13.9973(7) Å, c = 16.3818(10) Å, α = 69.365(5)°, β = 76.620(5)°, γ = 77.292(4)°, V = 2516.8(3) Å3, Z = 2, R gt(F) = 0.0540, wR ref(F 2) = 0.1413, T = 100.02(10) K.

Crystal structure of (3E,5E)-3,5-bis(4-cyanobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one, C27H18FN3O3S

C27H18FN3O3S, monoclinic, P21/c (no. 14), a = 8.091(6) Å, b = 42.84(3) Å, c = 7.096(6) Å, β = 107.806(10)°, V = 2342(3) Å3, Z = 4, R gt(F) = 0.0616, wR ref(F 2) = 0.1321, T = 173(2) K.